LGND: Ligand Pharma Kompaniya qiymatining sof foydaga nisbati

Ligand Pharmaceuticals Incorporated (LGND) korporativ emblemasi va logotipi

Litsenziyalash to'lovlarining barqaror oqimi va patent himoyasi Ligand Pharmaceuticals (LGND) uchun sezarli himoya to'siqlarini yaratadi. Kompaniyaning P/E baholanishi kapitalning cheklangan sharoitlarida istiqbolli molekulalar uchun raqobatni yaqqol namoyish etadi, bunda joriy holat 116.00 ga tengdir. Royalti to'lovlariga bo'lgan bunday pragmatik yondashuv professional brend imidjini ta'minlaydi va investitsiya risklarini yumshatadi.

LGND Ligand Corp: Narx-foyda koeffitsiyenti 04.07.2022 - 17.11.2026 oraligʻida

Ligand Pharmaceuticals Incorporated (LGND) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:Ligand Pharmaceuticals Incorporated - LGND
Ligand yetakchi tovari

P/E koeffitsiyenti sof foydaning bir birligining bozor qiymatini aks ettiradi, bu esa investorga investitsiyalarning qoplanish muddatini va aktivlarning haddan tashqari qimmat baholanganlik darajasini aniqlash imkonini beradi. Ligand Pharmaceuticals (LGND) kompaniyasining P/E qiymatidagi o'zgarishlarni tahlil qilish orqali Ligand Pharmaceuticals barqarorligini baholash mumkin, uning royalti-ga asoslangan modeli operatsion xarajatlarni minimallashtiradi va pul oqimini an'anaviy sog'liqni saqlash gigantlariga qaraganda yanada bashorat qilinadigan qiladi.

Raqobatdosh kompaniyalar tahlili

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Limited MENS|Amneal (AMRX) - Kapitalizatsiyaning foydaga nisbati|PRGO: Narx-foyda koeffitsiyenti|Alvotech SA - Bozor narxining sof foydaga nisbati|LQDA: P/E multiplikatori|Galapagos Genomics - Kompaniya qiymatining sof foydaga nisbati|ANIP (ANI Pharmaceuticals Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati mannkindcorp.com MNKD|Narxning foydaga nisbati Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SPRY (ARS Pharmaceuticals Inc)|Bozor narxining sof foydaga nisbati TBPH (Theravance)|AQST - Narxning foydaga nisbati|scPharmaceuticals (SCPH) - Narx-foyda koeffitsiyenti|TECX: P/E multiplikatori|Narx-foyda multiplikatori TNXP|Narxning foydaga nisbati China SXT Pharmaceuticals, Inc.|EPRX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHST|EXOZ - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ORMP (oramed.com)|P/E multiplikatori enterabio.com ENTX|HYFT - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ABVC BioPharma, Inc ABVC|CPIX: P/E multiplikatori|Quantum BioPharma Ltd - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti FGEN|Telomir Pharmaceuticals, Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)